This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
21 Sep 2011

CMC & Inspiration Sign Agreement for Hemophilia B Therapy

The two companies have announced Tuesday their agreement for the manufacture of bulk IB1001, a new therapy for the treatment and prevention of bleeding in individuals with hemophilia B.

CMC Biologics, a CMO of biopharmaceutical products, and Inspiration Biopharmaceuticals, a Nigel-based developer of treatments for hemophilia, have signed a long-term commercial supply agreement for the manufacture of bulk IB1001, Inspiration's intravenous recombinant factor IX (rFIX) product, for the treatment and prevention of bleeding in individuals with hemophilia B.

 

CMC will be the exclusive manufacturer of bulk IB1001 for at least six years; commercial supply manufacturing is expected to begin this fall.

 

IB1001 is close to completing the Phase III portion of clinical testing in Europe, the U.S., Israel and India. If approved, IB1001 is expected to be the second recombinant FIX product to come to the market for hemophilia B, providing addition

Related News